{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:38:09Z","timestamp":1785530289028,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41440-024-02084-w","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T09:50:30Z","timestamp":1737539430000},"page":"1554-1563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma"],"prefix":"10.1038","volume":"48","author":[{"given":"Elvira","family":"Fanelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Picca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Airale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Astarita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Mingrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Catarinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Votta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Colomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cesareo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Paladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Rabbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Veglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Milan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vallelonga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2084_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280\u201399.","journal-title":"Eur Heart J"},{"key":"2084_CR2","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","volume":"3","author":"W Li","year":"2017","unstructured":"Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular and thrombotic complications of novel Multiple Myeloma therapies: a review. JAMA Oncol. 2017;3:980\u20138.","journal-title":"JAMA Oncol"},{"key":"2084_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejphar.2018.09.014","volume":"838","author":"M Gavazzoni","year":"2018","unstructured":"Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, et al. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects. Eur J Pharmacol. 2018;838:85\u201390.","journal-title":"Eur J Pharmacol"},{"key":"2084_CR4","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"},{"key":"2084_CR5","doi-asserted-by":"crossref","unstructured":"Astarita A, Mingrone G, Airale L, Vallelonga F, Covella M, Catarinella C, et al. Multiple Myeloma patients undergoing carfilzomib: development and validation of a risk score for cardiovascular adverse events prediction. Cancers. 2021;13:1631.","DOI":"10.3390\/cancers13071631"},{"key":"2084_CR6","doi-asserted-by":"crossref","unstructured":"Parati G, Bilo G, Kollias A, Pengo M, Ochoa JE, Castiglioni P, et al. Blood pressure variability: methodological aspects, clinical relevance and practical indications for management\u2014a European Society of Hypertension position paper\u2217. J Hypertens. 2023;41:527\u201344.","DOI":"10.1097\/HJH.0000000000003363"},{"key":"2084_CR7","doi-asserted-by":"publisher","first-page":"i4098","DOI":"10.1136\/bmj.i4098","volume":"354","author":"SL Stevens","year":"2016","unstructured":"Stevens SL, Wood S, Koshiaris C, Law K, Glasziou P, Stevens RJ, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ. 2016;354:i4098.","journal-title":"BMJ"},{"key":"2084_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/ajh\/hpab125","volume":"35","author":"G \u00d6zkan","year":"2022","unstructured":"\u00d6zkan G, Ulusoy \u015e, Arici M, Derici \u00dc, Akpolat T, \u015eeng\u00fcl \u015e, et al. Does blood pressure variability affect hypertension development in prehypertensive patients? Am J Hypertens. 2022;35:73\u20138.","journal-title":"Am J Hypertens"},{"key":"2084_CR9","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"2084_CR10","doi-asserted-by":"crossref","unstructured":"Stergiou GS, Palatini P, Parati G, O\u2019brien E, Januszewicz A, Lurbe E, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39:1293\u20131302.","DOI":"10.1097\/HJH.0000000000002843"},{"key":"2084_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","volume":"32","author":"C Mitchell","year":"2019","unstructured":"Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1\u201364.","journal-title":"J Am Soc Echocardiogr"},{"key":"2084_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1\u201339.e14.","journal-title":"J Am Soc Echocardiogr"},{"key":"2084_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1161\/01.HYP.5.2.264","volume":"5","author":"M Di Rienzo","year":"1983","unstructured":"Di Rienzo M, Grassi G, Pedotti A, Mancia G. Continuous vs intermittent blood pressure measurements in estimating 24-hour average blood pressure. Hypertension. 1983;5:264\u20139.","journal-title":"Hypertension"},{"key":"2084_CR14","doi-asserted-by":"crossref","unstructured":"Mena L, Pintos S, Queipo NV, Aizp\u00farua JA, Maestre G, Sulbar\u00e1n T. A reliable index for the prognostic significance of blood pressure variability. J Hypertens. 2005;23:505\u201311.","DOI":"10.1097\/01.hjh.0000160205.81652.5a"},{"key":"2084_CR15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(10)60308-X","volume":"375","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Howard SC, Dolan E, O\u2019Brien E, Dobson JE, Dahl\u00f6f B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895\u2013905.","journal-title":"Lancet"},{"key":"2084_CR16","doi-asserted-by":"crossref","unstructured":"Bilo G, Giglio A, Styczkiewicz K, Caldara G, Maronati A, Kawecka-Jaszcz K, et al. A new method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall. J Hypertens. 2007;25:2058\u201366.","DOI":"10.1097\/HJH.0b013e32829c6a60"},{"key":"2084_CR17","doi-asserted-by":"crossref","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023;41:1874\u20132071.","DOI":"10.1097\/HJH.0000000000003480"},{"key":"2084_CR18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41440-023-01199-w","volume":"46","author":"K Narita","year":"2023","unstructured":"Narita K, Hoshide S, Kario K. Short- to long-term blood pressure variability: Current evidence and new evaluations. Hypertens Res. 2023;46:950\u20138.","journal-title":"Hypertens Res"},{"key":"2084_CR19","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","volume":"103","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, Milan A, Ferri C, W\u00e4sch R, Gay F, Larocca A, et al. Cardiovascular adverse events in modern myeloma therapy\u2014incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018;103:1422\u201332.","journal-title":"Haematologica"},{"key":"2084_CR20","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41440-019-0267-x","volume":"42","author":"F Vallelonga","year":"2019","unstructured":"Vallelonga F, Romagnolo A, Merola A, Sobrero G, Di Stefano C, Milazzo V, et al. Detection of orthostatic hypotension with ambulatory blood pressure monitoring in Parkinson\u2019s disease. Hypertens Res. 2019;42:1552\u201360.","journal-title":"Hypertens Res"},{"key":"2084_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00415-019-09244-w","volume":"266","author":"F Vallelonga","year":"2019","unstructured":"Vallelonga F, Di Stefano C, Merola A, Romagnolo A, Sobrero G, Milazzo V, et al. Blood pressure circadian rhythm alterations in alpha-synucleinopathies. J Neurol. 2019;266:1141\u201352.","journal-title":"J Neurol"},{"key":"2084_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.parkreldis.2018.06.032","volume":"56","author":"V Milazzo","year":"2018","unstructured":"Milazzo V, Di Stefano C, Vallelonga F, Sobrero G, Zibetti M, Romagnolo A, et al. Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease. Parkinsonism Relat Disord. 2018;56:82\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"2084_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/jhh.2013.45","volume":"27","author":"G Leoncini","year":"2013","unstructured":"Leoncini G, Viazzi F, Storace G, Deferrari G, Pontremoli R. Blood pressure variability and multiple organ damage in primary hypertension. J Hum Hypertens. 2013;27:663\u201370.","journal-title":"J Hum Hypertens"},{"key":"2084_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1161\/HYPERTENSIONAHA.107.088708","volume":"49","author":"G Mancia","year":"2007","unstructured":"Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, et al. Long-term prognostic value of blood pressure variability in the general population. Hypertension. 2007;49:1265\u201370.","journal-title":"Hypertension"},{"key":"2084_CR25","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1161\/HYPERTENSIONAHA.109.140798","volume":"55","author":"TW Hansen","year":"2010","unstructured":"Hansen TW, Thijs L, Li Y, Boggia J, Kikuya M, Bj\u00f6rklund-Bodeg\u00e5rd K, et al. Prognostic value of reading-to-reading blood pressure variability over 24\u2009h in 8938 subjects from 11 populations. Hypertension. 2010;55:1049\u201357.","journal-title":"Hypertension"},{"key":"2084_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/2047487319872572","volume":"27","author":"G Bilo","year":"2020","unstructured":"Bilo G, Dolan E, O\u2019Brien E, Facchetti R, Soranna D, Zambon A, et al. The impact of systolic and diastolic blood pressure variability on mortality is age dependent: data from the Dublin Outcome Study. Eur J Prev Cardiol. 2020;27:355\u201364.","journal-title":"Eur J Prev Cardiol"},{"key":"2084_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41440-020-0421-5","volume":"43","author":"G Parati","year":"2020","unstructured":"Parati G, Torlasco C, Pengo M, Bilo G, Ochoa JE. Blood pressure variability: its relevance for cardiovascular homeostasis and cardiovascular diseases. Hypertens Res. 2020;43:609\u201320.","journal-title":"Hypertens Res"},{"key":"2084_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1161\/HYPERTENSIONAHA.114.03694","volume":"64","author":"P Palatini","year":"2014","unstructured":"Palatini P, Reboldi G, Beilin LJ, Casiglia E, Eguchi K, Imai Y, et al. Added predictive value of night-time blood pressure variability for cardiovascular events and mortality. Hypertension. 2014;64:487\u201393.","journal-title":"Hypertension"},{"key":"2084_CR29","doi-asserted-by":"crossref","unstructured":"Palatini P, Saladini F, Mos L, Fania C, Mazzer A, Cozzio S, et al. Short-term blood pressure variability outweighs average 24-h blood pressure in the prediction of cardiovascular events in hypertension of the young. J Hypertens. 2019;37:1419\u201326.","DOI":"10.1097\/HJH.0000000000002074"},{"key":"2084_CR30","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1161\/01.CIR.102.13.1536","volume":"102","author":"D Sander","year":"2000","unstructured":"Sander D, Kukla C, Klingelh\u00f6fer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis. Circulation. 2000;102:1536\u201341.","journal-title":"Circulation"},{"key":"2084_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","volume":"5","author":"G Georgiopoulos","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, et al. Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies. JACC CardioOncol. 2023;5:1\u201321.","journal-title":"JACC CardioOncol"},{"key":"2084_CR32","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41440-023-01354-3","volume":"46","author":"H Tomiyama","year":"2023","unstructured":"Tomiyama H. Vascular function: a key player in hypertension. Hypertens Res. 2023;46:2145\u201358.","journal-title":"Hypertens Res"},{"key":"2084_CR33","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s00520-015-2648-2","volume":"23","author":"L Peng","year":"2015","unstructured":"Peng L, Ye X, Zhou Y, Zhang J, Zhao Q. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Support Care Cancer. 2015;23:2813\u201324.","journal-title":"Support Care Cancer"},{"key":"2084_CR34","doi-asserted-by":"crossref","unstructured":"Vallelonga F, Maule S. Diagnostic and therapeutical management of supine hypertension in autonomic failure: a review of the literature. J Hypertens. 2019;37:1102\u201311.","DOI":"10.1097\/HJH.0000000000002008"},{"key":"2084_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0532-4","volume":"16","author":"RA Rison","year":"2016","unstructured":"Rison RA, Beydoun SR. Paraproteinemic neuropathy: a practical review. BMC Neurol. 2016;16:13.","journal-title":"BMC Neurol"},{"key":"2084_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF02291401","volume":"6","author":"DS Goldstein","year":"1996","unstructured":"Goldstein DS, Mcrae A, Holmes C, Dalakas MC. Autoimmune autonomic failure in a patient with myeloma-associated Shy-Drager syndrome. Clin Auton Res. 1996;6:17\u201321.","journal-title":"Clin Auton Res"},{"key":"2084_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/jns.12428","volume":"26","author":"M Ballegaard","year":"2021","unstructured":"Ballegaard M, Nelson LM, Gimsing P. Comparing neuropathy in multiple myeloma and AL amyloidosis. J Peripher Nerv Syst. 2021;26:75\u201382.","journal-title":"J Peripher Nerv Syst"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-02084-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-02084-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-02084-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:42:19Z","timestamp":1744778539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-02084-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2084"],"URL":"https:\/\/doi.org\/10.1038\/s41440-024-02084-w","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Alberto Milan received honoraria for advisory board from Amgen. Sara Bringhen received honoraria from Bristol-Myers Squibb, Celgene, Amgen, and Janssen; advisory boards for Amgen, Karyopharm, Janssen, and Celgene; consultancy fees from Takeda and Janssen. Francesca Gay received honoraria from Amgen, Janseen, Celgene, BMS, Takeda, and Abbvie; advisory boards for Amgen, Janseen, Celgene, BMS, Takeda, and Abbvie; advisory adaptive for Roche Oncopeptides. The other authors declare no conflict of interest. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, and\/or interpretation of data; in the writing of the manuscript and\/or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}